Afinitor Disperz — CareFirst (Caremark)
neuroendocrine tumors of the gastrointestinal tract, lung, and thymus (carcinoid tumors)
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on current regimen
Approval duration
12 months